One study shows that 131I-labelled anti-HER2 VHHs bind to the epitopes that are distinct to the ones recognized by mAbs (Trastuzumab and Pertuzumab) in HER2+ breast cancer (103). Here, ERBB2 is linked to breast carcinoma.